Long-term response to lenalidomide in patients with newly diagnosed multiple myeloma

Leukemia. 2014 Feb;28(2):455-7. doi: 10.1038/leu.2013.300. Epub 2013 Oct 22.

Authors

T V Kourelis¹, S K Kumar¹, G Srivastava¹, M A Gertz¹, M Q Lacy¹, F K Buadi¹, R A Kyle¹, A Dispenzieri¹

Affiliation

¹ Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.

PMID: 24150218
DOI: 10.1038/leu.2013.300

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Immunologic Factors / administration & dosage
Immunologic Factors / therapeutic use*
Lenalidomide
Multiple Myeloma / diagnosis
Multiple Myeloma / drug therapy*
Multiple Myeloma / mortality
Thalidomide / administration & dosage
Thalidomide / analogs & derivatives*
Thalidomide / therapeutic use
Treatment Outcome

Substances

Immunologic Factors
Thalidomide
Lenalidomide